Neurocrine reported FY2025 revenue of $2.86 billion and Q1 2026 revenue of $815 million, making the thesis about whether profitable neuroscience growth can broaden while pipeline and commercialization risk stay controlled.
References
Sources used in this report
SEC datasetSEC company tickers exchange dataset2026-05-20 · Primary evidence for issuer identity, exchange, ticker and CIK.SEC APISEC submissions API2026-05-20 · Primary evidence for filing chronology and latest forms.SEC APISEC companyfacts API2026-05-20 · Primary evidence for financial statement facts used in the article and deck.SEC filingForm 10-K2026-02-11 · Annual business, risk and financial statement baseline.SEC filingForm 10-Q2026-05-05 · Latest interim financial statement baseline.SEC filingForm 8-K2026-05-18 · Recent event chronology.SEC filingDEF 14A2026-04-15 · Governance, meeting and incentive baseline.